Episode

Seegene's Episode

Seegene participated in the world’s largest clinical chemistry conference(AACC)

NEWS 2018.08.03


Seegene Inc. a company that specializes in molecular diagnosis participated in AACC - the world’s largest clinical lab expo held in Chicago, USA, from July 31st to August 2nd.

The AACC is a world class expo where medical diagnostics companies showcase the most recent information on diagnostic technology, reagents, equipment, testing methods and much more many invitro diagnostic experts from all over the world participate in it.

At this year’s AACC, Seegene introduced SGDDS (Seegene Digitalized Development System), a digital-based reagent development automation system, and introduced a various product lines that will be expanded rapidly through this system. SGDDS is a comprehensive system for design and developing reagents, and other basic experiments based on a biological information database. Seegene significantly shortens the time and cost of developing high multiplex real-time PCR assays by using this system, which can test and detect different kinds of viruses or bacterias at the same time, and has expanded the range of collaborative development from clinical fields such as infectious disease, genetic disease, drug resistance to the food, animal, and plant research field.

In addition, Seegene introduced SGSTAR (Seegene Same Day Testing and Reporting) which based on Seegene’s All-in-One platform that enables reporting of results on the day of test regardless of sample or test types. SGSTAR is a consolidated next-generation test platform that can apply various products randomly and enables up to 16 different test simultaneously when using STARlet IVD. SGSTAR, along with SGDDS, received much attention by showing its distinctive features.

Meanwhile, Seegene is expanding and targeting the Latin American market by establishing its subsidiary in Mexico as a bridgehead and introduced products for detecting infectious diseases such as respiratory infection, tuberculosis, sexually transmitted disease, drug resistance, and more. Moreover, given the regional characteristics of Latin America, Seegene received a request for a diagnostic product for detecting epidemiologic infections that are commonly found in tropical and subtropical climatic regions and Seegene is planning on developing customized product for the local market.

Previous Next List
Previous Seegene has participated in the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2018) 2018.04.30
Next Seegene HPV product evaluated to be appropriate for Australia’s national screening program 2018.10.04
home > News > EPISODE